Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators.
about
Peroxisome proliferator-activated receptors (PPARs) and ovarian function--implications for regulating steroidogenesis, differentiation, and tissue remodeling.PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancerThe Role of PPARs in CancerProline oxidase, a proapoptotic gene, is induced by troglitazone: evidence for both peroxisome proliferator-activated receptor gamma-dependent and -independent mechanismsCombined treatment with troglitazone and lovastatin inhibited epidermal growth factor-induced migration through the downregulation of cysteine-rich protein 61 in human anaplastic thyroid cancer cellsTherapeutic Implications of PPARgamma in Human Osteosarcoma.Peroxisome proliferator-activated receptor-gamma 34C>G polymorphism and colorectal cancer risk: a meta-analysis.Lipid phosphate phosphatase-2 activity regulates S-phase entry of the cell cycle in Rat2 fibroblasts.The anti-tumor activity of Mikania micrantha aqueous extract in vitro and in vivo.Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case-control studyCoffee component hydroxyl hydroquinone (HHQ) as a putative ligand for PPAR gamma and implications in breast cancer.PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells.Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivoExpression of peroxisome proliferator activated receptor gamma and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma.Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer.Potential therapeutic role of peroxisome proliferator activated receptor-gamma agonists in psoriasis.Energy Balance, Myostatin, and GILZ: Factors Regulating Adipocyte Differentiation in Belly and Bone.Peroxisome proliferator-activated receptor-gamma ligands as bone turnover modulators.A consideration of PPAR-gamma ligands with respect to lipophilicity: current trends and perspectives.Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.Peroxisome proliferator-activated receptor-gamma ligands as investigational modulators of angiogenesis.The prince and the pauper. A tale of anticancer targeted agents.Doinseunggitang ameliorates endothelial dysfunction in diabetic atherosclerosisPeroxisome Proliferator-Activated Receptor-gamma Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer.Isoflavones and the prevention of breast and prostate cancer: new perspectives opened by nutrigenomics.The Role of PPAR Ligands in Controlling Growth-Related Gene Expression and their Interaction with Lipoperoxidation Products.PPARalpha Ligands as Antitumorigenic and Antiangiogenic AgentsA comparison of peroxisome proliferator-activated receptor-α agonist and antagonist on human umbilical vein endothelial cells angiogenesisPPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury.Intestinal PPARγ signalling is required for sympathetic nervous system activation in response to caloric restriction.Peroxisome proliferator-activated receptor γ and colorectal cancer.Protective Effects of Turbinaria ornata and Padina pavonia against Azoxymethane-Induced Colon Carcinogenesis through Modulation of PPAR Gamma, NF-κB and Oxidative Stress.Restoration of C/EBPα in dedifferentiated liposarcoma induces G2/M cell cycle arrest and apoptosis.Expression of peroxisome proliferator activated receptor-gamma (PPAR-γ) in human non-small cell lung carcinoma: correlation with clinicopathological parameters, proliferation and apoptosis related molecules and patients' survival.Differential ontogenetic exposure to obesogenic environment induces hyperproliferative status and nuclear receptors imbalance in the rat prostate at adulthood.Peroxisome proliferator-activated receptor-gamma1 is dephosphorylated and degraded during BAY 11-7085-induced synovial fibroblast apoptosis.The Effects of Combined Treatment with an HMG-CoA Reductase Inhibitor and PPARγ Agonist on the Activation of Rat Pancreatic Stellate Cells.
P2860
Q21245560-78A45F08-C13E-439E-B2D6-D43596C388B1Q21328702-EA432AA7-399F-40C3-B6BB-0519A4C61BD4Q21342955-1751704D-6A0A-45CE-B204-D9E4CFC9D444Q28283135-84CBEDE3-0EDF-428C-92A8-DC48370635FCQ28543879-3B5B0334-B24A-4176-ADD3-D0DC7A738217Q33674615-F9E7226C-D7EB-4669-9589-2A2F0F66E334Q33830757-AE7B2861-8CE6-4B4F-B5DE-B25079B1DB8CQ34492882-F9922AF4-C20B-4F97-BFB5-AD1D7D5FEA0AQ34582023-D41EAE8F-045D-47BD-AED8-67E5B5207CB2Q34990890-B2431F60-AC01-4AAB-9AB8-7002A84BAF0CQ35101709-5ED3EDDC-A32F-434E-B333-381FE91A7546Q35216293-9B3C0A62-5C41-4FC0-B49F-9773FC7F954CQ35249254-7AB32F68-9FD4-47FE-9642-688FEA7DCFFDQ35748476-85270AF0-C590-4734-8415-CB2438F12C20Q35770556-30433586-896F-4EA1-B38C-869798CB9256Q36187022-4F43E87A-5DC9-4F0B-8CE5-141B8E80D42FQ36221953-AD477B40-832C-48CE-AB70-54A79BA98B9BQ36465015-8C10BE03-3A47-4A1A-AAA7-0A003A177B7BQ36715753-AA253530-9492-49AA-83EB-E979C1EFAB8DQ36763993-2C3F16F3-CE60-4BC4-B53D-C37028C1EC57Q36830195-E8706F12-E7E6-4F89-9416-0E5FD86C7534Q36885846-F78FE872-8723-4337-A788-37563CCE94CFQ36888347-B3168FEB-F5DA-4BC8-9B6F-C754233DD393Q36964693-A85CDB3D-987F-48D2-A523-3C3E447EC670Q37042365-B1CB0756-E1DF-42B1-ADDD-DDF0616D5100Q37155989-00A2E71C-C9DA-4B31-AF5F-D2486B7592A9Q37157524-35078E0F-D45C-4E47-90A1-5360F4DD434FQ37173328-DB0AA8EE-464D-44B1-A530-3C7A462FF6B4Q37211832-53CA4C21-35CC-45E9-8035-C2BA6FC87437Q37251719-B37E025D-36EC-4EC1-9E69-0B31326AE9A0Q37271564-3AF2C61C-E29E-4009-BAB6-6F9FA9372353Q37362740-A3C562CB-F21B-43E7-AB17-17C44D884830Q37419913-66DD2E06-EB26-444A-A8AF-CEAED41DBDD1Q37821269-C7296CD1-5513-471B-92EC-3A6A472EF0EAQ38910306-5FD7AEB7-B8F7-4D7F-8134-CD6F960332EFQ39428312-F53CAFD1-C4DE-46EF-96FE-A5091722EE0FQ39639581-281BEF72-2A9B-4BC4-830A-817C995D4B0AQ40021711-78BF8125-BA28-4DA3-98CE-35849FEC65A8Q40269148-888BC1E3-089A-439B-BDE1-0656021E9D65Q41995936-FA0BD953-CC74-4C4F-A681-17E061505FCA
P2860
Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators.
@ast
Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators.
@en
type
label
Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators.
@ast
Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators.
@en
prefLabel
Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators.
@ast
Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators.
@en
P2093
P1476
Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators.
@en
P2093
Alexandra Margeli
Gregory Kouraklis
Philippe Vielh
Stamos Theocharis
P304
P356
10.1016/J.CTRV.2004.04.004
P577
2004-10-01T00:00:00Z